Cargando…

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design

INTRODUCTION: Forced vital capacity is the only registrational endpoint in idiopathic pulmonary fibrosis clinical trials. As most new treatments will be administered on top of standard of care, estimating treatment response will become more challenging. We developed a simulation model to quantify va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santermans, Eva, Ford, Paul, Kreuter, Michael, Verbruggen, Nadia, Meyvisch, Paul, Wuyts, Wim A., Brown, Kevin K., Lederer, David J., Byrne, Adam J., Molyneaux, Philip L., Sivananthan, Arunon, Moor, Catharina C., Maher, Toby M., Wijsenbeek, Marlies
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822798/ https://www.ncbi.nlm.nih.gov/pubmed/31565781 http://dx.doi.org/10.1007/s12325-019-01093-3

Ejemplares similares

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
por: Kreuter, Michael, et al.
Publicado: (2020)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Managing Fatigue in Patients With Interstitial Lung Disease
por: Kahlmann, Vivienne, et al.
Publicado: (2020)

Role of the internet of medical things in care for patients with interstitial lung disease
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

Communicating with patients with idiopathic pulmonary fibrosis: can we do it better?
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry
por: Moor, Catharina C., et al.
Publicado: (2020)

The world is not enough – the value of increasing registry data in idiopathic pulmonary fibrosis
por: Moor, C. C., et al.
Publicado: (2020)

Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis
por: Wijsenbeek, Marlies S., et al.
Publicado: (2015)

Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis
por: Moor, Catharina C., et al.
Publicado: (2019)

Educational aspects of rare and orphan lung diseases
por: Alfaro, Tiago M., et al.
Publicado: (2021)

Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population
por: Kahlmann, Vivienne, et al.
Publicado: (2021)

Desquamative interstitial pneumonia: a systematic review of its features and outcomes
por: Hellemons, Merel E., et al.
Publicado: (2020)

Comprehensive Care for Patients with Sarcoidosis
por: Moor, Catharina C., et al.
Publicado: (2020)

Exhaled breath analysis in interstitial lung disease
por: van der Sar, Iris G., et al.
Publicado: (2023)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2020)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
por: Richeldi, Luca, et al.
Publicado: (2023)

Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: a pilot study
por: Moor, Catharina C, et al.
Publicado: (2020)

ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey
por: Powell, Pippa, et al.
Publicado: (2019)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey
por: Moor, Catharina C., et al.
Publicado: (2019)

Editorial: Interstitial Lung Disease Around the World
por: Wijsenbeek, Marlies, et al.
Publicado: (2022)

The flare of care for rare: per aspera ad astra for rare lung diseases!
por: Wijsenbeek, Marlies, et al.
Publicado: (2023)

The Shorter, the Better: Can We Improve Efficiency of Idiopathic Pulmonary Fibrosis Trials?
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly
por: Guler, Sabina A., et al.
Publicado: (2022)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t94gkajp4dd7bf8uqnu8bq61u8